Applicable Principles
5 Each of the parties referred to the recent review of authorities and applicable principles in Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 2) [2019] FCA 657 (Pfizer No 2). At [25] of Pfizer No 2 Burley J summarised the relevant principles:
(1) The jurisdiction to order preliminary discovery is an extraordinary one since an order for preliminary discovery involves an invasion of the prospective respondent's private affairs in order to determine whether or not a case can properly be brought against the prospective respondent; J & A Vaughan Super Pty Ltd v Becton Property Group Limited [2013] FCA 340 at [17] (Kenny J); C7 Pty Ltd v Foxtel Management Pty Ltd [2001] FCA 1864 at [50] (Gyles J).
(2) In considering where the balance lies in ordering costs, the exceptional nature of the jurisdiction is a matter to be taken into consideration and is a matter that may mean that a wholly successful prospective applicant is not entitled to an order for costs; ObjectiVision Pty Ltd v Visionsearch Pty Ltd (No 3) [2015] FCA 304 at [23] (Perry J); Cobankara v Australia and New Zealand Banking Group Ltd [2017] FCA 419 at [20] (Mortimer J).
(3) In Cappuccio v Australia & New Zealand Banking Group Ltd [1999] FCA 1188, a case where an application for preliminary discovery was resolved by consent, Burchett J at [3] considered that the appropriateness of the costs order:
…depends very much on the consequences of the discovery obtained. If the applicant for preliminary discovery uncovers enough to enable that applicant to bring proceedings which are successful, there may be much to be said for the proposition that the costs of the preliminary discovery should form part of the costs of the action. On the other hand, if the applicant proceeds, brings an action, fails, and is ordered to pay the costs of that action, there seems every reason why, generally speaking, the costs of the preliminary discovery should be included in the costs payable to the respondent.
(4) Following this approach, in a number of cases where a prospective applicant has been successful in procuring orders for preliminary discovery, courts have found it appropriate to order that the payment of costs be deferred to see whether the outcome of the production of documents yields the commencement of substantive proceedings (usually within a specified period of time following the preliminary discovery proceedings). When that has occurred, then the award of costs has been left to the decision-maker in the substantive proceedings; Cappuccio at [3] - [5]; SmithKline Beecham plc v Alphapharm Pty Ltd [2001] FCA 271 at [32] (Finkelstein J); E D Oates Pty Ltd v Edgar Edmondson Imports [2012] FCA 356 at [59] (Kenny J); Gearhart United Pty Ltd v Omni Oil Technologies (Asia) SDN BHD (No 2) [2010] FCA 558 at [24] (Besanko J); Procter v Kalivis (No 3) [2010] FCA 1194; Aristocrat Technologies Australia Pty Limited v Ainsworth Game Technology Limited (No 2) [2019] FCA 511 at [10] - [11] (Yates J).
(5) In other cases, the view has been expressed that the costs outcome should be determined at the time the outcome of the preliminary discovery application has been determined. It is a discrete issue and should not be deferred to an uncertain time; C7 Pty Ltd at [50]; Steffen v ANZ Banking Group [2009] NSWSC 883 at [31] (McDougall J); ObjectiVision at [17] - [21].
(6) Where an order for costs has not been deferred, some authorities indicate that the costs balance should favour the payment of costs by the prospective applicant. This is because there is no obligation on a prospective respondent to respond to requests for information, and a prospective respondent is entitled to remain passive and consequently put a prospective applicant to proof in preliminary discovery hearings: Glencore International AG v Selwyn Mines Limited [2005] FCA 801; 223 ALR 238 [15] (Lindgren J); C7 Pty Ltd at [50]; Vaughan Super at [18]; Procter at [17].
(7) However, where the prospective respondent takes an adversarial approach to the application, it exposes itself to an order for costs; Steffen at [32] - [33]; ObjectiVision at [23] - [24]; Dallas Buyers Club LLC v iiNet Limited (No 3) [2015] FCA 422; 327 ALR 695 at [3] (Perram J). In these cases, the courts have preferred not to defer the making of costs orders.
6 To this list his Honour added the following (at [26] and [27]):
It is true to say, as has been observed in some of the authorities to date, that there has been no uniform approach to the award of costs in relation to preliminary discovery applications. However, an emerging thread is that where a prospective respondent takes an adversarial approach to the application, it may be required to bear some or all of the costs in the event that the prospective applicant is successful. The rationale behind that approach may be explained by the extraordinary nature of the preliminary discovery jurisdiction, which is intended to facilitate the making of sensible decisions concerning the commencement of proceedings, before proceedings have been formulated. Accordingly, whilst an adversarial approach is not prohibited, it is to be discouraged. Preliminary discovery is not a process by which potential parties are to open up new fronts for litigation warfare, but a procedure by which the efficient conduct of litigation is promoted; [Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCAFC 193; 257 FCR 62] [2], [4] (Allsop CJ), [119] (Perram J).
Where a prospective respondent elects to enter the fray and vigorously contest the application, it becomes exposed to the risk that it should bear a costs consequence similar to the position it would be in were it a party to proceedings proper. Where the contest on an application is limited to the prospective applicant being put to proof of the elements of r 7.23, then even a successful prospective applicant may be liable to pay the costs. Conversely, where each point is hard fought, the prospective respondent is exposed to the risk that it will be visited with some or all of the costs in the event they are unsuccessful. In such circumstances, it may be inappropriate to defer a costs order to the outcome of any prospective litigation.
7 The substance of the Pfizer litigation concerned an application by Pfizer for preliminary discovery in order to ascertain whether the respondent, referred to as SBA, had infringed certain patents. Further details of the grounds for the application are not relevant. Burley J at first instance refused the application: Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285. However, his Honour's decision was overturned on appeal and remitted back to him on the question of costs: Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCAFC 193; 257 FCR 62 (Pfizer No 1) per Allsop CJ, Perram and Nicholas JJ all writing separately.
8 The original hearing of the preliminary discovery application in Pfizer ran for two days. The application raised matters of significance regarding the application of the preliminary discovery procedure to highly confidential intellectual property rights, and their interface with Australia's international obligations: Pfizer No 1, per Allsop CJ at [4]. Burley J described the litigation as being "hard fought", and the approach of the respondent as doing "more than simply put Pfizer to proof of the elements of r 7.23": Pfizer No 2, at [28]. Despite this, his Honour rejected Pfizer's argument that SBA had not acted in accordance with its obligations under ss 37M and 37N of the FCA Act, noting that "SBA was entitled to challenge the case brought, particularly having regard to its legitimate concerns regarding the confidentiality of the documents … [b]ut in doing so, it became exposed to an adverse order for costs" (at [28]).
9 Burley J also refused to defer the question of costs until it was apparent whether Pfizer commenced substantive proceedings or not (at [30]). His Honour stated that "[w]hilst that approach might be appropriate where no adversarial approach had been taken, it is not suitable here" (at [30]).
10 Ultimately, his Honour granted Pfizer 50% of its costs. His Honour reasoned that SBA's defence to the application was to cause a "mini-trial", and therefore it was exposed to a costs order, but that Pfizer should not be awarded full costs due invoking the "extraordinary jurisdiction of the court to achieve intrusive orders for the production by SBA of its highly confidential documents" (at [30]).